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Abstract 
 
Background 
The European Quality of Life-5 Dimensions (EQ-5D) instrument combines questionnaire responses 
into a single utility estimate using country-specific value sets (VS). Countries without a national VS are 
advised to select a VS based on geographic proximity. In the absence of a Swiss VS we used foreign 
VS to gain insights into their appropriateness for use with Swiss cancer patients.  
Methods 
EQ-5D health states and visual analogue scale (VAS) ratings were collected in one German and three 
Swiss oncology trials. Utilities were calculated based on the United Kingdom (UK), German (GE), 
French (FR) and European Union (EU) VS. Resulting differences and Pearson partial correlation 
coefficients with corresponding VAS ratings were assessed.  
Results 
In total, 202 Swiss and 154 German patients undergoing cancer treatment completed at least 2 EQ-5D 
forms. The mean difference between GE-based and FR-, UK- or EU-based utilities was significantly 
larger than the differences between the latter. The absolute mean difference between utilities and VAS 
ratings was highest for GE-based utilities, for Swiss (0.170, 95%CI 0.146-0.194) and German patients 
(0.174, 95%CI 0.145-0.202). The correlation between GE-based utilities and VAS ratings was the 
lowest (r=0.36, 95%CI 0.33-0.40); the highest was between FR-based utilities and VAS ratings 
(r=0.43, 95%CI 0.39-0.46). 
Conclusion 
For Switzerland, utility calculations based on the German or French VS would be an obvious choice. 
Our results suggest that the German VS may not be the most appropriate for use with Swiss cancer 
patients. The French and European Union VS may be relevant alternatives and improve international 
comparability. 
Keywords: EQ-5D, visual analogue scale, Switzerland, Germany, utility  
Key points for decision makers  
• In the absence of a national value set, the choice of a foreign value set for calculating EQ-5D 
utilities requires caution 
• Compared to other European value sets the German value set may result in higher utilities 
• Results of cost-utility calculations may be influenced by the chosen value set  
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Background 
The European Quality of Life-5 Dimensions (EQ-5D) instrument [1] is widely used as a basis for 
estimating health state preferences (utilities). Results are typically used to calculate quality-adjusted 
life years (QALYs) in the context of cost-utility analysis. The EQ-5D questionnaire uses a descriptive 
system covering five dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression). There are three possible response categories for each, indicating no problems, 
some problems or severe problems, resulting in 243 possible health states. The instrument is 
complemented by a visual analogue scale (VAS) that allows individuals to rate their overall health 
state on a scale of 0 to 100. The VAS achieves a purely patient-based rating of health-related quality 
of life when used with clinical populations. In contrast, the responses to the EQ-5D questionnaire items 
are combined into a single utility estimate using country-specific scoring algorithms and value sets that 
are derived from general population-based time trade-off (TTO) or VAS studies [2, 3]. Patients' 
descriptions of real health states are thus combined with public preferences for hypothetical health 
states, in order to take into account societal preferences. Many studies have looked into the impact of 
different health state valuation methods or have provided cross-national comparisons of preference 
values [3-9], in order to ensure that comparability across countries is achieved [10]. Differences 
between the values assigned to health states in different countries are thought to be due to differences 
both in survey and analysis methods and in societal preferences and cultural differences. If no national 
value set is available for a given country the general advice is to select a value set based on 
geographic proximity [10]. However, value sets from foreign countries may not represent local societal 
values and can cause misleading results in cost-utility studies.  
No Swiss value set exists to transform questionnaire-based EQ-5D health states reported by Swiss 
patients into utilities. The most obvious value sets to be used with Swiss patients would be the 
German [11] and French [12] ones, since Switzerland borders on both Germany and France. These 
two languages are spoken in different parts of Switzerland. Use of the European Union value set may 
be an alternative [13]. It is unclear, however, which of these foreign value sets would yield the most 
appropriate utility scores and best reflect Swiss culture.  
In several oncology trials performed by the Swiss Group for Clinical Cancer Research (SAKK), as well 
as in a study conducted in German cancer patients, EQ-5D is part of the prospective health economic 
data collection. In the Swiss trials, patients with advanced breast cancer (SAKK 24/09), esophageal 
cancer (SAKK 75/08) or hepatocellular cancer (SAKK 77/08) were enrolled. The German trial 
(CESAR-TDM-C-III-002) enrolled patients with advanced lung cancer. In order to evaluate the impact 
of different value sets on utility estimates for these patients undergoing cancer treatment, we apply the 
German (TTO-based), French (TTO-based), United Kingdom (TTO-based) and European Union (VAS-
based, study carried out in six Western European countries) value sets. The results achieved by 
applying the VAS based European Union value set are not based on choice under uncertainty and 
hence not utilities in a strict sense but, formally spoken, values or preferences [14]; for simplicity we 
still describe them as utilities in the context of this analysis. EQ-5D data from German patients were 
included to evaluate whether possible discrepancies between utilities calculated by applying the 
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various value sets to Swiss patients are a purely Swiss phenomenon or can also be observed in a 
German cancer patient population. 
In the absence of a Swiss EQ-5D value set the overall aim of this study is to compare the application 
of four foreign value sets and to gain insights into their appropriateness for use with Swiss cancer 
patients. 
Methods 
So far, no methodology has been described that could serve as a basis for determining which foreign 
value set should be used to calculate country-specific utilities from questionnaire-based EQ-5D health 
states, if there is no national value set in place. In this study, we used a series of tentative approaches 
to compare the performance of different value sets. Utilities were calculated from patient-reported, 
questionnaire-based EQ-5D health states using the above-referenced candidate value sets. We 
subsequently assessed how the results differed from each other in terms of observed averages and 
how they were correlated. It was also assessed how they differed from the purely patient-based VAS 
ratings, and how they correlated with these [15]. The assumption behind this approach was that minor 
differences between utility scores resulting from different value sets and high correlations would 
indicate comparable valuations. Similar differences and correlations between utilities resulting from 
different value sets and VAS ratings would indicate a similar relationship with VAS ratings and hence a 
higher degree of agreement and interchangeability of value sets.  
Patients  
EQ-5D questionnaires were completed and VAS ratings were provided by patients enrolled in one 
German and three Swiss clinical cancer trials. The first Swiss trial involves advanced breast cancer 
patients receiving first-line treatment with chemotherapy and bevacizumab (SAKK 24/09, 
NCT01131195). It started in September 2010. The second Swiss trial involves patients with locally 
advanced esophageal cancer treated with chemotherapy (with or without cetuximab), radiotherapy and 
surgery (SAKK 75/08, NCT01107639). It started in May 2009. The third Swiss trial involves patients 
with advanced liver cancer (hepatocellular carcinoma) treated with sorafenib with or without 
everolimus (SAKK 77/08, NCT01005199). It started in December 2009. The German study involves 
advanced lung cancer patients treated with chemotherapy (Central European Society for Anticancer 
Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring (CEPAC-TDM), NCT01326767). 
It started in March 2011. Patients completed the EQ-5D according to the clinical visit schedule of each 
study. An EQ-5D data extraction was made at the end of October 2012 while all studies were still 
ongoing. Data to be used for the present study included all fully completed forms; incomplete forms 
(with one or more questions not answered or VAS item missing) were excluded. In addition, only forms 
of patients who had completed a minimum of 2 forms were included in the analyses. 
Data preparation and statistical analyses 
For each completed EQ-5D questionnaire, utilities were calculated using the German (EQGE utility), 
European Union (EQEU utility), French (EQFR utility), and United Kingdom (EQUK utility) value sets 
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and calculation algorithms as described elsewhere. VAS ratings (ranging from 0 to 100) were divided 
by 100 in order to bring them to the same scale as used for the utility scores.  
Descriptive statistics were performed to describe mean age of patients and number of completed EQ-
5D forms per trial for both genders. The distribution of answer categories per questionnaire item was 
also analyzed. The distribution of utilities and VAS ratings was shown in turnip plots. 
A mean EQ-5D utility per value set and a mean VAS score were calculated for every single patient. 
Thereafter, differences between mean utilities (EQGE-EQFR, EQGE-EQUK, EQGE-EQEU, etc.) and 
between mean utility and VAS score (EQGE-VAS, EQUK-VAS, EQFR-VAS etc.) were computed. 
These differences were assessed for statistical significance using a global linear mixed model 
controlling for gender, age and trial (only Swiss patients), with patients treated as a random factor. 
This analysis was performed separately for Swiss and German patients. Results were reported as 
predicted least square means (see Electronic Supplementary Material). 
Pearson correlations between the utilities resulting from the different value sets and the VAS ratings 
were also calculated. To control for gender, age and trial (also covering cancer type) utilities and VAS 
ratings were also modelled using a mixed linear model with patients treated as a random factor and 
repeated measures for forms (controlling for the effect of patients clustered within trials). Subsequently 
the computed residuals for each utility and VAS were correlated. Pearson’s correlation coefficients as 
well as Fischer’s 95% confidence intervals were computed.  
All analyses were performed using SAS® version 9.2, SAS Institute, Cary, NC. 
Results 
Patients 
From May 2010 to October 2012 a total of 356 patients (202 (56.7%) Swiss and 154 (43.3%) German) 
in four different trials completed at least 2 EQ-5D forms (see table 1). The mean age of all patients 
was 62 years (standard deviation=9.4, Min-Max=24-85). On average, patients completed 6.2 forms 
(standard deviation=3.3, Min-Max=2-22); the study that had started first (SAKK77/08) had the highest 
average number of completed forms (8.7). More male (59%) than female patients (41%) were 
included. 
Utilities and VAS ratings 
The EQ-5D dimension most often reported to be impaired in the study populations was “Pain and 
Discomfort”. In over 50% of the forms, the response categories of moderate or extreme pain or 
discomfort were used. The second most impaired dimension was anxiety and depression with almost 
35% of the forms using the response categories representing moderately to extremely anxious or 
depressed (see figure 1). Some problems with daily activity were reported in 30% of all forms.  
Patients from trial SAKK 75/08 (oesophageal cancer) showed the highest mean utilities (EQGE 0.92, 
95%CI 0.90-0.94, to EQEU 0.83, 95%CI 0.81-0.86) and VAS ratings (0.76, 95%CI 0.73-0.79); patients 
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from trial SAKK 77/08 (liver cancer) showed the lowest utilities (EQGE 0.83, 95%CI 0.79-0.88, to 
EQEU 0.71, 95%CI 0.66-0.76) and VAS ratings (0.66, 95%CI 0.61-0.70). No large differences were 
observed between male and female patients (see table 2). 
The overall mean utility (over all forms and patients) was at least 0.1 higher for the EQGE (0.87, 
95%CI 0.85-0.88) value set compared to the EQUK (0.77, 95%CI 0.75-0.79), EQFR (0.77, 95%CI 
0.74-0.79) and EQEU (0.76, 95%CI 0.75-0.78) value sets. The average VAS score (0.69, 95%CI 0.67-
0.71) was 0.18-0.08 lower than the respective utility scores (table 2, figure 2). 
Differences between utilities based on German, French, European Union and United Kingdom 
value sets 
For the Swiss patients, differences between EQGE-EQFR, EQGE-EQUK and EQGE-EQEU utilities 
were significantly greater than differences between EQUK-EQEU, EQUK-EQFR or EQEU-EQFR 
utilities. The greatest difference was seen for EQGE-EQEU (0.107, 95%CI 0.098-0.116). In addition, 
the EQFR-EQEU difference was significantly greater than the EQFR-EQUK difference (see Electronic 
Supplementary Material).  In the Swiss patients, the results were significantly influenced by trial 
(p=0.0003, estimate SAKK75/08 vs SAKK 77/08=-0.02510, estimate SAKK24/09 vs SAKK 77/08=-
0.03048), gender (p=0.0246, estimate female vs male=0.02534) and age (p=0.0005, estimate=-
0.00078 per additional year of age). Comparable results were seen for German patients. Marked 
differences were seen between EQGE and EQFR of 0.116 (95%CI 0.104-0.127), EQGE and EQUK of 
0.106 (95%CI 0.095-0.118) and EQGE and EQEU of 0.111 (95%CI 0.099-0.122) utility scores, 
whereas differences for EQFR, EQUK and EQEU utility scores were close to zero and non-significant 
(see Figure 3). In the German patients only gender (p=0.036, estimate female versus male=0.01464) 
showed a significant effect.  
Correlation between utilities based on German, French, European Union and United Kingdom 
value sets 
Correlations between utilities based on the German, French, European Union and United Kingdom 
value sets were calculated on the basis of unadjusted results (without correcting for potential 
confounding by gender, age and clinical trial) as well as regression residuals resulting from the mixed 
linear model correcting for gender, age and clinical trial. In both cases, the EQGE utility scores 
showed the lowest correlation with EQFR (regression method: 0.87, 95%CI 0.861 – 0.881) and EQEU 
utility scores (regression method: 0.87, 95%CI 0.861 – 0.881). Highest correlations were seen 
between EQUK and EQGE (regression method: 0.96, 95%CI 0.954 – 0.961) and EQUK and EQEU 
(regression method: 0.96, 95%CI 0.965 – 0.970) scores (see Figure 4). 
Differences between utilities based on German, French, European Union and United Kingdom 
value sets and VAS ratings 
Overall VAS ratings were lower than the utilities calculated using the various value sets. Analysis of 
differences between VAS and utility scores using a global linear mixed model showed that the 
difference was greatest between EQGE utilities and VAS for Swiss patients (0.170, 95%CI 0.146-
7 
 
0.194). This difference was significantly greater than for the EQFR (0.077, 95%CI 0.053-0.101), EQUK 
(0.074, 95%CI 0.050 – 0.098,) or EQEU (0.067, 95%CI 0.043-0.091,) utilities (see Figure 3). For Swiss 
patients, the trial, gender and age had no significant effect on the results. Similar results were seen for 
the German patients. The difference between the EQGE utilities and VAS for German patients was 
0.174 (95%CI 0.145 – 0.202) and was significantly greater than that observed for VAS and EQFR- 
utility scores (0.061, 95%CI 0.033-0.089), VAS and EQUK utility scores (0.070, 95%CI 0.042-0.099) 
and VAS and EQEU utility scores (0.066, 95%CI 0.038-0.094). For German patients, only gender 
(p=0.048, female vs male estimate = -0.05564) showed a significant effect. 
Correlation between utilities and VAS ratings 
Correlations between the EQGE, EQFR, EQUK and EQEU utilities and VAS ratings were calculated 
on the basis of unadjusted results and regression residuals as described above. The unadjusted 
correlation coefficient for the EQGE utility with VAS scores (0.45, 95%CI 0.41-0.48) was significantly 
lower than EQFR (0.55, 95%CI 0.52-0.58), EQUK (0.51, 95%CI 0.48-0.54) and EQEU utilities (0.54, 
95%CI 0.51-0.57) with VAS scores. After controlling for gender, age and trial, the correlation 
coefficients were about 0.1 lower and no significant differences between the individual value sets were 
observed (see figure 3). However the EQGE / VAS correlation coefficient (0.36, 95%CI 0.33-0.40) was 
again lowest and the EQFR/VAS correlation coefficient (0.43, 95%CI 0.39-0.46) was highest. 
Discussion  
In the absence of a Swiss EQ-5D value set we have estimated questionnaire-based EQ-5D utilities for 
Swiss and German cancer patients participating in one of four clinical oncology trials using the 
German, French, European Union and United Kingdom value sets. For countries without an own 
national value set the EuroQol group recommends the use of a value set based on geographic 
proximity. Therefore, in the case of Switzerland, the German [11] or French [12] value sets may be 
considered. However, as almost 23% (2011) of the population living permanently in Switzerland are 
foreigners, most of whom come from other European countries, the European Union [13] value set 
may also be considered. In the absence of a clear decision criterion and with implications for health 
economic analysis in mind, the aim of our study was to compare the application of the available value 
sets to questionnaire-based EQ-5D data and VAS ratings from Swiss patients.  
Utilities based on the German value set are on average 0.1 higher than utilities based on the French, 
European Union or United Kingdom value sets, whereas the differences between the latter are all 
close to zero. This was observed for both Swiss and German patients. Heijnk et al.[5] have reported 
that the German value set generates higher quality-adjusted life years in summary measures of 
population health than the United Kingdom value set.  Furthermore Gunther et al. [16] showed that, for 
patients with depression, utilities calculated with the German value set are higher than those 
calculated with the United Kingdom value set. Stark et al. also reported higher utility scores resulting 
from the German value set versus the United Kingdom value set in German inflammatory bowel 
disease patients [17]. These observations may indicate that differences between EQGE and EQUK 
utilities are disease independent. Our results show that, for cancer patients from both Switzerland and 
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Germany, utilities calculated with the German value set are higher than those calculated with the 
French, European Union or United Kingdom value sets. One reason may be that the cancer patients 
included in this study often reported that they had “some problems with daily activities” or were “unable 
to perform daily activities”, which in the German value set has no direct impact on the resulting utility. 
In addition, the response category “I am moderately anxious or depressed” is used in one third of the 
forms; this also has no impact on utility when the German value set is used. Therefore, it can be 
questioned whether the German value set is generally suitable for cancer patients. The two cancer-
relevant dimensions of daily activity (impaired by tiredness) and anxiety/depression have only a 
minimal impact when this value set is used. 
For both Swiss and German cancer patients, the difference between utilities based on the German 
value set and VAS ratings (0.172) is more than 0.1 greater than that between the utilities based on the 
other 3 value sets and VAS ratings (0.069). That VAS ratings in a general population render lower 
scores than valuations based on the time trade-off method has been described by Badia et al. [18]. In 
a review study, Pickard et al.[19] report the same phenomenon for cancer patients, who showed lower 
VAS ratings than EQ-5D utilities across all reviewed cancer studies. For patients with diabetes or 
chronic obstructive pulmonary disease [20], similar findings have been described, with VAS ratings 
lower than utilities. VAS ratings higher than utilities have been reported for inflammatory bowel 
syndrome patients [17]. Our results are in agreement with these observations; however, to the best of 
our knowledge we are the first to show that the magnitude of the differences between utility and VAS 
scores may heavily depend on the value set used to calculate the EQ-5D utility scores. 
Whynes et al describe a correspondence between questionnaire-based EQ-5D utilities calculated with 
the United Kingdom value set and VAS ratings [15]. However, so far, there has been no direct 
comparison of the correlations between questionnaire-based EQ-5D utilities calculated with different 
value sets, and VAS ratings. Our results show that correlations between VAS ratings and 
questionnaire-based EQ-5D utilities depend on the value set used. In our case, use of the German 
value set results in the lowest correlation. The EQFR, EQEU and EQUK utilities all show a similar 
correlation with VAS ratings. It is clear that higher correlations and degree of similarity between 
questionnaire-based EQ-5D utilities and VAS ratings cannot be interpreted as a per se indicator of 
better suitability of a value set, due to the conceptual differences between the two types of measures 
[15, 21]. Nonetheless, Whyne et al. [15] found that EQ VAS scores are predictable from EQ-5D health 
state classifications”, indicating that some degree of correlation can be expected. The deviant result 
for the EQGE utilities therefore indicates a need for caution and further scrutiny.  
The fact that all these phenomena are seen for both Swiss and German patients suggests that the 
German value set and algorithm itself rather than national/cultural differences may cause the issues 
described. The German value set was developed with a relatively small sample of the German 
population (n=334) compared to the United Kingdom (n=3395). This might have led to non-significant 
regression results for the above mentioned dimensions in the validation process. It would be of interest 
to verify the robustness of these results in a larger study. 
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Our study has some weaknesses to be considered. It is based on cancer patients (on active 
treatment) only. Whether or not a study of Swiss patients with other diseases would give similar results 
is unknown and should be the subject of future research. Switzerland has three major language 
regions (German, French and Italian) and the Swiss patients could choose which language form they 
preferred to complete given their spoken or best understood language. In our study we did not control 
for this language effect. Such linguistic complexity may make it more difficult to choose an appropriate 
foreign value set for Swiss patients. Should the French-speaking part of the population be valued with 
the French value set, as proposed by Perneger et al. [22], and the German-speaking population with 
the German value set? And what about Italian-speaking patients? A study that involves completion of 
the EQ-5D questionnaire by a representative general population sample from all over Switzerland 
might help to address this issue. The development of a Swiss value set could also be considered but 
may be impeded by the fact that Switzerland is a small country with 4 language regions and relevant 
cultural differences. Switzerland also has a large foreign population (about 23% in 2012). The 
development of the EQ5D-5L questionnaire, with a standardized study design to elicit value sets in 
different countries, may improve international comparability. However, this will not necessarily solve 
the issue of country specific differences and uncertainty in situations where no local value set exists. . 
Conclusion 
Although use of the German value set leads to outlying results in comparison with the French, 
European Union and United Kingdom value sets, there is no gold standard or decision criterion 
available that would allow us to make a finite statement on the suitability of the different datasets. We 
still see substantial hints that the German value set may not be the most suitable one for use with 
Swiss cancer patients. Depending on the anticipated analysis the French and European Union value 
sets are relevant alternatives and may improve international comparability. 
In health economic evaluations based on the trials included here, using the German value set would 
lead to higher quality adjusted life time results than the French or European Union value sets. 
Situations might occur where cost-utility estimates would be biased towards the optimistic. In order to 
gauge incremental cost effectiveness ratios (ICER) in health economic studies alongside clinical trials 
in Swiss patients, one seems to be well advised to use utilities based on several value sets (and on 
VAS ratings to achieve a pure patient perspective). It is currently inappropriate to estimate the ICER 
and the corresponding level of cost effectiveness based on a single value set. 
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Table 1 Patient characteristics 
 
 Age Number of completed in forms 
N 
Mean 
STDEV 
Median Min-Max 
Mean 
STDEV 
Median 
Min-
Max 
All 356 
62.1 
9.4 
63.0 24-85 
6.2 
3.3 
5 2-22 
Trial 
SAKK 24/09° 
breast cancer 
92 
59.9 
12.2 
62.5 24-83 
6.8 
3.8 
6 2-20 
SAKK 75/08° 
esophageal cancer 
72 
63.2 
7.6 
63.0 42-77 
6.7 
2.2 
6 3-12 
SAKK 77/08° 
Hepatocellular cancer 
38 
65.7 
9.6 
66.5 48-85 
8.7 
5.0 
9 2-22 
CESAR C-III-002* 
lung cancer 
154 
62.1 
7.9 
62 40-77 
5.1 
2.3 
5 2-11 
Gender 
Male 210 
63.2 
8.3 
63 40-85 
6.2 
3.2 
5 2-22 
Female 146 
60.6 
10.7 
62 24-83 
6.3 
3.5 
6 2-20 
Legend: °=Swiss studies, *=German study, STDEV=standard deviation 
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Table 2 Mean VAS and EQ-5D utility scores 
   VAS Utility EQGE Utility EQUK Utility EQFR Utility EQEU 
 
 N 
Mean 
Median 
(95%CI) 
Mean 
Median 
(95%CI) 
Mean 
Median 
(95%CI) 
Mean 
Median 
(95%CI) 
Mean 
Median 
(95%CI) 
 
All 356 
0.69 
0.71 
(0.67-0.71) 
0.87 
0.9 
(0.85-0.88) 
0.77  
0.79  
(0.75-0.79) 
0.77  
0.82 
(0.74-0.79) 
0.76  
0.77 
(0.75-0.78) 
A
ge
 
<50 34 
0.70 
0.71 
(0.64-0.77) 
0.87 
0.88 
(0.84-0.91) 
0.75  
0.73  
(0.70-0.80) 
0.76  
0.8 
(0.70-0.82) 
0.74  
0.72 
(0.69-0.78) 
50-59 98 
0.68 
0.71 
(0.64-0.72) 
0.87 
0.89 
(0.85-0.89) 
0.76  
0.77  
(0.73-0.79) 
0.76  
0.79 
(0.72-0.79) 
0.75  
0.75 
(0.72-0.78) 
60-69 137 
0.69 
0.72 
(0.66-0.73) 
0.86  
0.92  
(0.83-0.89) 
0.77  
0.82  
(0.73-0.80) 
0.77  
0.84 
(0.74-0.81) 
0.77  
0.80 
(0.74-0.80) 
>69 87 
0.69 
0.70 
(0.66-0.73) 
0.87 
0.89 
(0.84-0.90) 
0.78  
0.82  
(0.74-0.82) 
0.77  
0.83 
(0.72-0.81) 
0.77  
0.80 
(0.74-0.81) 
Tr
ia
l 
SAKK 24/09 
breast  
cancer 
92 
0.69 
0.71 
(0.65-0.73) 
0.86 
0.89 
(0.83-0.89) 
0.76  
0.79  
(0.72-0.80) 
0.75 
0.82 
(0.70-0.80) 
0.75  
0.76 
(0.71-0.79) 
SAKK 75/08 
esophageal  
cancer 
72 
0.76 
0.78 
(0.73-0.79) 
0.92 
0.93 
(0.90-0.94) 
0.84  
0.86  
(0.81-0.87) 
0.86  
0.89 
(0.83-0.89) 
0.83  
0.85 
(0.81-0.86) 
SAKK 77/08 
hepatocellular 
cancer 
38 
0.66 
0.66 
(0.61-0.70) 
0.83 
0.87 
(0.79-0.88) 
0.72  
0.74  
(0.66-0.77) 
0.71  
0.76 
(0.64-0.78) 
0.71  
0.72 
(0.66-0.76) 
CESAR C-III-002 
lung 
cancer 
154 
0.67 
0.69 
(0.64-0.7) 
0.85 
0.89 
(0.83-0.88) 
0.75  
0.76  
(0.72-0.78) 
0.74  
0.78 
(0.71-0.77) 
0.75  
0.75 
(0.72-0.77) 
G
en
de
r 
Female 146 
0.70 
0.71 
(0.67-0.73) 
0.87 
0.9 
(0.84-0.89) 
0.76  
0.78  
(0.73-0.79) 
0.75  
0.81 
(0.72-0.79) 
0.75  
0.75 
(0.72-0.77) 
Male 210 
0.6 
0.71 
(0.67-0.71) 
0.87 
0.9 
(0.85-0.88) 
0.78  
0.8  
(0.75-0.80) 
0.78  
0.82 
(0.75-0.81) 
0.77  
0.78 
(0.75-0.79) 
C
ou
nt
ry
 
Switzerland 202 
0.71 
0.73 
(0.69-0.73) 
0.88 
0.91 
(0.86-0.89) 
0.78  
0.81  
(0.76-0.80) 
0.78  
0.84 
(0.76-0.81) 
0.77  
0.79 
(0.75-0.80) 
Germany 154 
0.67 
0.69 
(0.64-0.70) 
0.85 
0.89 
(0.83-0.88) 
0.75  
0.76  
(0.72-0.78) 
0.74  
0.78 
(0.71-0.77) 
0.75  
0.75 
(0.72-0.77) 
Legend: VAS=Visual analogue scale, EQGE=utility according to German value set, EQUK=utility 
according to United Kingdom value set, EQFR= utility according to French value set, EQEU= utility 
according to European Union value set 
  
13 
 
Figure 1 Percentage answers per question for the EQ-5D questionnaire 
 
Figure 2 Turnip plots of average EQ-5D utility and VAS scores per patient 
 
Legend: VAS=Visual analogue scale, GE=German value set, UK=United Kingdom value set, 
FR=French value set, EU= European Union value set 
Figure 3 Differences between German, French, European Union and United Kingdom value set based 
EQ-5D utility scores and VAS and between utility scores for Swiss and German patients. 
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Legend: += least square mean, * significant,    = 95%CI German patients,  = 95%CI Swiss patients,  
VAS=Visual analogue scale, CH= Swiss, EQGE= utility according to German value set, EQUK= utility 
according to United Kingdom value set, EQFR= utility according to French value set, EQEU=utility 
according to European Union value set 
 
Figure 4 Correlation of VAS and EQ-5D utilities according to GE, FR, UK and EU value sets  
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Legend: ●= correlation coefficient for raw data, ●= correlation coefficient for residual method, ├─┤= 
95% confidence interval, VAS=Visual analogue scale, EQGE= utility according to German value set, 
EQUK= utility according to United Kingdom value set, EQFR= utility according to French value set, 
EQEU=utility according to European Union value set  
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